Lobbying Filing Details

Total Spending

$710,000

Activities

5

Lobbyists

5

Gov't Entities

20

Filing Information
Filing UUID:
cb8007cd-7dc7-401a-9211-1a60ebb5e929
Type:
Q2 - 2nd Quarter - Report
Period:
2015 - 2nd Quarter (Apr 1 - June 30)
Date Posted:
July 20, 2015 at 8:44 PM
Income:
$0
Expenses:
$710,000
Expense Method:
Method C - Reporting amounts under section 162(e) of the Internal Revenue Code
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Christian Cruz
Registrant
ASSOCIATION FOR ACCESSIBLE MEDICINES

Association representing the interests of the generic pharmaceutical industry.

Washington, District of Columbia
Client
ASSOCIATION FOR ACCESSIBLE MEDICINES
District of Columbia, United States of America
Lobbying Activities (5)
Activity 1
Budget/Appropriations

FDA Funding, H.R. 1078 FDA Safety Over Sequestration Act, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for Fiscal Year 2016

Lobbyists (4)
  • MR. JASON R MONEY
  • MR. CHRISTOPHER DAVIS
  • MELISSA SCHULMAN
  • HEIDI WILSON
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Office of Management & Budget (OMB)
  • Health & Human Services, Dept of (HHS)
Activity 2
Copyright/Patent/Trademark

H.R. 9 The Innovation Act, S. 632 STRONG Patents Act, S. 1137 Patent Act

Lobbyists (4)
  • MR. JASON R MONEY
  • MR. CHRISTOPHER DAVIS
  • MELISSA SCHULMAN
  • HEIDI WILSON
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Office of Management & Budget (OMB)
  • Health & Human Services, Dept of (HHS)
Activity 3
Medicare/Medicaid

Medicare Part D Program and Generic Drugs,H.R. 2391 Medicaid Generic Drug Price Fairness Act, S. 1364 Medicaid Generic Drug Price Fairness Act

Lobbyists (4)
  • MR. JASON R MONEY
  • MR. CHRISTOPHER DAVIS
  • MELISSA SCHULMAN
  • HEIDI WILSON
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Office of Management & Budget (OMB)
  • Health & Human Services, Dept of (HHS)
Activity 4
Pharmacy

Implementation of FDASIA and GDUFA,Labeling of Generic Drugs, Biosimilars Naming, Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products, H.R. 6 21st Century Cures Act, Innovation for Healthier Americans Initiative, Prescription Drug Pricing, Abuse-Deterrent Prescription Drug Formulations,H.R. 971 Orphan Product Extensions Now Accelerating Cures and Treatments Act, S. 1421 Orphan Product Extensions Now Accelerating Cures and Treatments Act,H.R. 2841 FAST Generics Act

Lobbyists (5)
  • MR. JASON R MONEY
  • MR. CHRISTOPHER DAVIS
  • CHRISTINE SIMMON
  • MELISSA SCHULMAN
  • HEIDI WILSON
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Office of Management & Budget (OMB)
  • Health & Human Services, Dept of (HHS)
Activity 5
Trade (domestic/foreign)

H.R. 1890 Bipartisan Congressional Trade Priorities and Accountability Act, S. 995 Bipartisan Congressional Trade Priorities and Accountability Act

Lobbyists (2)
  • MR. CHRISTOPHER DAVIS
  • MELISSA SCHULMAN
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Office of Management & Budget (OMB)
  • Health & Human Services, Dept of (HHS)

Source: LDA.gov, data retrieved November 4, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.